Bogdan Mitran

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(6):E1972-1972
Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(12):3347-3358
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):17710
Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):17086
Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
Article: SCIENTIFIC REPORTS. 2019;9(1):14907
Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Article: CANCERS. 2019;11(9):E1371-1371
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
Mitran B; Varasteh Z; Abouzayed A; Rinne SS; Puuvuori E; De Rosa M; Larhed M; Tolmachev V; Orlova A; Rosenstrom U
Article: PHARMACEUTICS. 2019;11(8):E380-380
Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.
Oroujeni M; Abouzayed A; Lundmark F; Mitran B; Orlova A; Tolmachev V; Rosenström U
Article: PHARMACEUTICS. 2019;11(7):E358-358
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Abouzayed A; Yim C-B; Mitran B; Rinne SS; Tolmachev V; Larhed M; Rosenström U; Orlova A
Article: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2019;140:109-120
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Article: SCIENTIFIC REPORTS. 2019;9(1):6779
Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Article: BIOMATERIALS. 2019;203:73-85
Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.
Westerlund K; Vorobyeva A; Mitran B; Orlova A; Tolmachev V; Karlström AE; Altai M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2019;54(4):1209-1220
Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Article: MOLECULAR PHARMACEUTICS. 2019;16(3):995-1008
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019;20(5):E1080-1080
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: SCIENTIFIC REPORTS. 2019;9(1):655
Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Article: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2019;134:37-48
Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
Article: ONCOLOGY REPORTS. 2019;41(1):534-542
Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.
Mitran B; Andersson KG; Lindström E; Garousi J; Rosestedt M; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Article: JOURNAL OF CONTROLLED RELEASE. 2018;288:84-95
Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist P-H; Tolmachev V; Orlova A; Gräslund T
Article: CELLS. 2018;7(9):E141-141
Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Article: AMINO ACIDS. 2018;50(8):981-994
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.
Oroujeni M; Andersson KG; Steinhardt X; Altai M; Orlova A; Mitran B; Vorobyeva A; Garousi J; Tolmachev V; Löfblom J
Visa fler

Alla övriga publikationer

Review: CURRENT MEDICINAL CHEMISTRY. 2020;27(41):7090-7111
Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties.
Mitran B; Tolmachev V; Orlova A

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI